Top

Published in:

Open Access 01-12-2010 | Research

Predictive value of progression-related gene classifier in primary non-muscle invasive bladder cancer

Authors: Wun-Jae Kim, Eun-Jung Kim, Seon-Kyu Kim, Yong-June Kim, Yun-Sok Ha, Pildu Jeong, Min-Ju Kim, Seok-Joong Yun, Keon Myung Lee, Sung-Kwon Moon, Sang-Cheol Lee, Eun-Jong Cha, Suk-Chul Bae

Published in: Molecular Cancer | Issue 1/2010

Abstract

Background

While several molecular markers of bladder cancer prognosis have been identified, the limited value of current prognostic markers has created the need for new molecular indicators of bladder cancer outcomes. The aim of this study was to identify genetic signatures associated with disease prognosis in bladder cancer.

Results

We used 272 primary bladder cancer specimens for microarray analysis and real-time reverse transcriptase polymerase chain reaction (RT-PCR) analysis. Microarray gene expression analysis of randomly selected 165 primary bladder cancer specimens as an original cohort was carried out. Risk scores were applied to stratify prognosis-related gene classifiers. Prognosis-related gene classifiers were individually analyzed with tumor invasiveness (non-muscle invasive bladder cancer [NMIBC] and muscle invasive bladder cancer [MIBC]) and prognosis. We validated selected gene classifiers using RT-PCR in the original (165) and independent (107) cohorts. Ninety-seven genes related to disease progression among NMIBC patients were identified by microarray data analysis. Eight genes, a progression-related gene classifier in NMIBC, were selected for RT-PCR. The progression-related gene classifier in patients with NMIBC was closely correlated with progression in both original and independent cohorts. Furthermore, no patient with NMIBC in the good-prognosis signature group experienced cancer progression.

Conclusions

We identified progression-related gene classifier that has strong predictive value for determining disease outcome in NMIBC. This gene classifier could assist in selecting NMIBC patients who might benefit from more aggressive therapeutic intervention or surveillance.

Available only for authorised users

Cordon-Cardo C, Zhang ZF, Dalbagni G, Drobnjak M, Charytonowicz E, Hu SX, Xu HJ, Reuter VE, Benedict WF: Cooperative effects of p53 and pRB alterations in primary superficial bladder tumors. Cancer Res. 1997, 57: 1217-1221.PubMed

Habuchi T, Marberger M, Droller MJ, Hemstreet GP, Grossman HB, Schalken JA, Schmitz-Drager BJ, Murphy WM, Bono AV, Goebell P: Prognostic markers for bladder cancer: International Consensus Panel on bladder tumor markers. Urology. 2005, 66: 64-74. 10.1016/j.urology.2005.08.065CrossRefPubMed

Liou LS: Urothelial cancer biomarkers for detection and surveillance. Urology. 2006, 67: 25-33. discussion 33-24, 10.1016/j.urology.2006.01.034CrossRefPubMed

Bubendorf L: High-throughput microarray technologies: from genomics to clinics. Eur Urol. 2001, 40: 231-238. 10.1159/000049777CrossRefPubMed

Quackenbush J: Microarray analysis and tumor classification. N Engl J Med. 2006, 354: 2463-2472. 10.1056/NEJMra042342CrossRefPubMed

Kim WJ, Bae SC: Molecular biomarkers in urothelial bladder cancer. Cancer Sci. 2008, 99: 646-652. 10.1111/j.1349-7006.2008.00735.xCrossRefPubMed

Kim WJ, Quan C: Genetic and epigenetic aspects of bladder cancer. J Cell Biochem. 2005, 95: 24-33. 10.1002/jcb.20412CrossRefPubMed

Sorlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H, Hastie T, Eisen MB, Rijn van de M, Jeffrey SS: Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA. 2001, 98: 10869-10874. 10.1073/pnas.191367098PubMedCentralCrossRefPubMed

Beer DG, Kardia SL, Huang CC, Giordano TJ, Levin AM, Misek DE, Lin L, Chen G, Gharib TG, Thomas DG: Gene-expression profiles predict survival of patients with lung adenocarcinoma. Nat Med. 2002, 8: 819-824.

10.

Vijver van de MJ, He YD, van't Veer LJ, Dai H, Hart AA, Voskuil DW, Schreiber GJ, Peterse JL, Roberts C, Marton MJ: A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med. 2002, 347: 1999-2009. 10.1056/NEJMoa021967CrossRefPubMed

11.

Kihara C, Tsunoda T, Tanaka T, Yamana H, Furukawa Y, Ono K, Kitahara O, Zembutsu H, Yanagawa R, Hirata K: Prediction of sensitivity of esophageal tumors to adjuvant chemotherapy by cDNA microarray analysis of gene-expression profiles. Cancer Res. 2001, 61: 6474-6479.PubMed

12.

van 't Veer LJ, Dai H, Vijver van de MJ, He YD, Hart AA, Mao M, Peterse HL, Kooy van der K, Marton MJ, Witteveen AT: Gene expression profiling predicts clinical outcome of breast cancer. Nature. 2002, 415: 530-536. 10.1038/415530aCrossRefPubMed

13.

Kallioniemi O: Medicine: profile of a tumour. Nature. 2004, 428: 379-382. 10.1038/428379bCrossRefPubMed

14.

American Joint Committee on Cancer: Urinary bladder. American Joint Committee on Cancer: Cancer Staging Manual. Edited by: Greene FL. 2002, 335-340. New York, NY, Springer, 6CrossRef

15.

Reuter VE, Melamed MR: The lower urinary tract. Diagnostic Surgical Pathology. Edited by: Sternberg SS. 1989, 1355-1392. New York, NY, Raven Press

16.

Babjuk M, Oosterlinck W, Sylvester R, Kaasinen E, Bohle A, Palou-Redorta J: EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder. Eur Urol. 2008, 54: 303-314. 10.1016/j.eururo.2008.04.051CrossRefPubMed

17.

Hall MC, Chang SS, Dalbagni G, Pruthi RS, Seigne JD, Skinner EC, Wolf JS, Schellhammer PF: Guideline for the management of nonmuscle invasive bladder cancer (stages Ta, T1, and Tis): 2007 update. J Urol. 2007, 178: 2314-2330. 10.1016/j.juro.2007.09.003CrossRefPubMed

18.

Stenzl A, Cowan NC, De Santis M, Jakse G, Kuczyk MA, Merseburger AS, Ribal MJ, Sherif A, Witjes JA: The Updated EAU Guidelines on Muscle-Invasive and Metastatic Bladder Cancer. Eur Urol. 2009

19.

Bolstad BM, Irizarry RA, Astrand M, Speed TP: A comparison of normalization methods for high density oligonucleotide array data based on variance and bias. Bioinformatics. 2003, 19: 185-193. 10.1093/bioinformatics/19.2.185CrossRefPubMed

20.

Eisen MB, Spellman PT, Brown PO, Botstein D: Cluster analysis and display of genome-wide expression patterns. Proc Natl Acad Sci USA. 1998, 95: 14863-14868. 10.1073/pnas.95.25.14863PubMedCentralCrossRefPubMed

21.

Chen HY, Yu SL, Chen CH, Chang GC, Chen CY, Yuan A, Cheng CL, Wang CH, Terng HJ, Kao SF: A five-gene signature and clinical outcome in non-small-cell lung cancer. N Engl J Med. 2007, 356: 11-20. 10.1056/NEJMoa060096CrossRefPubMed

22.

Lossos IS, Czerwinski DK, Alizadeh AA, Wechser MA, Tibshirani R, Botstein D, Levy R: Prediction of survival in diffuse large-B-cell lymphoma based on the expression of six genes. N Engl J Med. 2004, 350: 1828-1837. 10.1056/NEJMoa032520CrossRefPubMed

23.

Skrzypski M, Jassem E, Taron M, Sanchez JJ, Mendez P, Rzyman W, Gulida G, Raz D, Jablons D, Provencio M: Three-gene expression signature predicts survival in early-stage squamous cell carcinoma of the lung. Clin Cancer Res. 2008, 14: 4794-4799. 10.1158/1078-0432.CCR-08-0576CrossRefPubMed

24.

Paik S, Shak S, Tang G, Kim C, Baker J, Cronin M, Baehner FL, Walker MG, Watson D, Park T: A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med. 2004, 351: 2817-2826. 10.1056/NEJMoa041588CrossRefPubMed

25.

Sanchez-Carbayo M, Socci ND, Lozano J, Saint F, Cordon-Cardo C: Defining molecular profiles of poor outcome in patients with invasive bladder cancer using oligonucleotide microarrays. J Clin Oncol. 2006, 24: 778-789. 10.1200/JCO.2005.03.2375CrossRefPubMed

26.

Dyrskjot L, Zieger K, Real FX, Malats N, Carrato A, Hurst C, Kotwal S, Knowles M, Malmstrom PU, de la Torre M: Gene expression signatures predict outcome in non-muscle-invasive bladder carcinoma: a multicenter validation study. Clin Cancer Res. 2007, 13: 3545-3551. 10.1158/1078-0432.CCR-06-2940CrossRefPubMed

27.

Dyrskjot L, Thykjaer T, Kruhoffer M, Jensen JL, Marcussen N, Hamilton-Dutoit S, Wolf H, Orntoft TF: Identifying distinct classes of bladder carcinoma using microarrays. Nat Genet. 2003, 33: 90-96. 10.1038/ng1061CrossRefPubMed

28.

Dupuy A, Simon RM: Critical review of published microarray studies for cancer outcome and guidelines on statistical analysis and reporting. J Natl Cancer Inst. 2007, 99: 147-157. 10.1093/jnci/djk018CrossRefPubMed

29.

Chuaqui RF, Bonner RF, Best CJ, Gillespie JW, Flaig MJ, Hewitt SM, Phillips JL, Krizman DB, Tangrea MA, Ahram M: Post-analysis follow-up and validation of microarray experiments. Nat Genet. 2002, 32 (Suppl): 509-514. 10.1038/ng1034CrossRefPubMed

30.

Michiels S, Koscielny S, Hill C: Prediction of cancer outcome with microarrays: a multiple random validation strategy. Lancet. 2005, 365: 488-492. 10.1016/S0140-6736(05)17866-0CrossRefPubMed

31.

Yao R, Davidson DD, Lopez-Beltran A, MacLennan GT, Montironi R, Cheng L: The S100 proteins for screening and prognostic grading of bladder cancer. Histol Histopathol. 2007, 22: 1025-1032.PubMed

32.

Bobarykina AY, Minchenko DO, Opentanova IL, Moenner M, Caro J, Esumi H, Minchenko OH: Hypoxic regulation of PFKFB-3 and PFKFB-4 gene expression in gastric and pancreatic cancer cell lines and expression of PFKFB genes in gastric cancers. Acta Biochim Pol. 2006, 53: 789-799.PubMed

33.

Minchenko OH, Ochiai A, Opentanova IL, Ogura T, Minchenko DO, Caro J, Komisarenko SV, Esumi H: Overexpression of 6-phosphofructo-2-kinase/fructose-2, 6-bisphosphatase-4 in the human breast and colon malignant tumors. Biochimie. 2005, 87: 1005-1010. 10.1016/j.biochi.2005.04.007CrossRefPubMed

34.

Loboda A, Jazwa A, Grochot-Przeczek A, Rutkowski AJ, Cisowski J, Agarwal A, Jozkowicz A, Dulak J: Heme oxygenase-1 and the vascular bed: from molecular mechanisms to therapeutic opportunities. Antioxid Redox Signal. 2008, 10: 1767-1812. 10.1089/ars.2008.2043CrossRefPubMed

35.

Huang SK, Chiu AW, Pu YS, Huang YK, Chung CJ, Tsai HJ, Yang MH, Chen CJ, Hsueh YM: Arsenic methylation capability, heme oxygenase-1 and NADPH quinone oxidoreductase-1 genetic polymorphisms and the stage and grade of urothelial carcinomas. Urol Int. 2008, 80: 405-412. 10.1159/000132699CrossRefPubMed

36.

Christopher SA, Diegelman P, Porter CW, Kruger WD: Methylthioadenosine phosphorylase, a gene frequently codeleted with p16(cdkN2a/ARF), acts as a tumor suppressor in a breast cancer cell line. Cancer Res. 2002, 62: 6639-6644.PubMed

37.

Lee JR, Shin H, Ko J, Choi J, Lee H, Kim E: Characterization of the movement of the kinesin motor KIF1A in living cultured neurons. J Biol Chem. 2003, 278: 2624-2629. 10.1074/jbc.M211152200CrossRefPubMed

38.

Tuckwell D: Evolution of von Willebrand factor A (VWA) domains. Biochem Soc Trans. 1999, 27: 835-840.CrossRefPubMed

39.

Sylvester RJ, Meijden van der AP, Oosterlinck W, Witjes JA, Bouffioux C, Denis L, Newling DW, Kurth K: Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials. Eur Urol. 2006, 49: 466-465. discussion 475-467, 10.1016/j.eururo.2005.12.031CrossRefPubMed

Title: Predictive value of progression-related gene classifier in primary non-muscle invasive bladder cancer
Authors: Wun-Jae Kim
Eun-Jung Kim
Seon-Kyu Kim
Yong-June Kim
Yun-Sok Ha
Pildu Jeong
Min-Ju Kim
Seok-Joong Yun
Keon Myung Lee
Sung-Kwon Moon
Sang-Cheol Lee
Eun-Jong Cha
Suk-Chul Bae
Publication date: 01-12-2010
Publisher: BioMed Central
Published in: Molecular Cancer / Issue 1/2010
Electronic ISSN: 1476-4598
DOI: https://doi.org/10.1186/1476-4598-9-3

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 1/2010

Maslinic acid potentiates the anti-tumor activity of tumor necrosis factor α by inhibiting NF-κB signaling pathway

Increased accumulation of hypoxia-inducible factor-1α with reduced transcriptional activity mediates the antitumor effect of triptolide

Developmental and oncogenic effects of Insulin-like Growth Factor-I in Ptc1+/- mouse cerebellum

Regulation of MCP-1 chemokine transcription by p53

Inositol 1,4,5-trisphosphate-induced Ca2+ signalling is involved in estradiol-induced breast cancer epithelial cell growth

Depletion of the oncoprotein Bcl-3 induces centrosome amplification and aneuploidy in cancer cells

Keynote webinar | Spotlight on antibody–drug conjugates in cancer